PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Veliparib

Drugs in development · updated 30 October 2026

Veliparib: clinical trials and development status

Other names and codes: ABT-888

NLM verified identityNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 Veliparib is in 13 active clinical trials (recruiting or ongoing, phases I–III) for 32 diseases. The most advanced phase is II–III.

13Active trials
II–IIIMost advanced phase
32Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Veliparib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 32 diseases.

DiseaseMost advanced phaseActive trialsReference trial
GlioblastomaII–III2NCT02152982
GliosarcomaII–III1NCT02152982
Breast neoplasmII4NCT01042379
MetastasisI–II2NCT01012817
Ovarian neoplasmI–II2NCT01012817
Triple-negative breast neoplasmII2NCT01042379
Acute myeloid leukemiaII1NCT03289910
Adenocarcinoma of the lungI–II1NCT01386385
AstrocytomaII1NCT03581292
Atypical chronic myeloid leukemiaII1NCT03289910
Bronchiolo-alveolar adenocarcinomaI–II1NCT01386385
Chronic myelomonocytic leukemiaII1NCT03289910
Fallopian tube neoplasmI–II1NCT01012817
GliomaII1NCT03581292
HemangiosarcomaII1NCT01042379
Lung small cell carcinomaII1NCT01638546
Myelodysplastic–myeloproliferative diseasesII1NCT03289910
MyelofibrosisII1NCT03289910
NeoplasmII1NCT01042379
Pancreatic neoplasmII1NCT01585805
Polycythemia veraII1NCT03289910
Thrombocythemia, EssentialII1NCT03289910
Endometrial neoplasmI1NCT01366144
Esophageal neoplasmI1NCT01366144
Head and neck neoplasmsI1NCT01366144
Liver failureI1NCT01366144
Lung neoplasmI1NCT01366144
MelanomaI1NCT01366144
Neoplasms, Unknown PrimaryI1NCT01366144
Renal InsufficiencyI1NCT01366144

Everything on Veliparib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch